Sublingual immunotherapy in preschool children with allergic rhinitis

JRCT ID: jRCT1031200292

Registered date:13/01/2021

Basic Information

• Recruitment status: Not Recruiting
• Health condition(s) or Problem(s) studied: Allergic rhinitis
• Date of first enrollment: 18/05/2021
• Target sample size: 90
• Study type: Interventional
• Intervention(s): Patients aged 1 to 4 years with perennial allergic rhinitis are randomized to the A: intervention group or B: control group. Patients in Group A take a house dust mite sublingual immunotherapy tablet once a day for 12 months.

Outcome(s)

• Primary Outcome: Improvement in nasal and eye symptom scores after 1 year

Secondary Outcome

1.Improvement in medication scores after 1 year
2.Frequency of adverse reactions
3.Changes in blood variables
4.Sensitization to other inhaled antigens

Key inclusion & exclusion criteria

• Age minimum: >= 1age old
• Age maximum: <= 4age old
• Gender: Both

Include criteria

1.Patients with perennial allergic rhinitis symptoms
2.Patients with allergic rhinitis who have a specific IgE RAST score of 1 for Dermatophagoides pteronyssinus and D. farinae
3.Diagnosis of perennial allergic rhinitis by a doctor

Exclude criteria

1.Patients with severe bronchial asthma
2.Patients with severe atopic dermatitis
3.Patients who have dogs and cats

Related Information

• Primary Sponsor: Ebisawa Motohiro
• Source(s) of Monetary Support: National Hospital Organization